Seattle Genetics, Abbott expand antibody deal

Seattle Genetics Inc. (NASDAQ:SGEN) and Abbott Laboratories (NYSE:ABT) expanded a 2011 deal for Seattle Genetics' antibody-drug conjugate (ADC) technology. Abbott will pay Seattle Genetics' $25 millio...